isoniazid has been researched along with Drug Abuse, Intravenous in 24 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a randomized trial with a factorial design comparing strategies for improving adherence to isoniazid preventive therapy in 300 injection drug users with reactive tuberculin tests and no evidence of active tuberculosis." | 9.09 | A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. ( Barnes, GL; Cavalcante, S; Chaisson, RE; Hackman, J; Kimbrough , L; Metha, S; Moore, RD; Watkinson, L, 2001) |
| "Isoniazid (INH) chemoprophylaxis has a positive impact on the development of clinical tuberculosis." | 7.71 | Reduction of clinical tuberculosis in HIV-infected males with isoniazid prophylaxis. ( Alaei, A; Alaei, K; Mansouri, D, 2002) |
| "Treatment of latent Mycobacterium tuberculosis infection with isoniazid can cause hepatotoxicity, but the risk of isoniazid-associated hepatotoxicity among persons coinfected with hepatitis C virus (HCV) is unknown." | 7.71 | Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. ( Astemborski, J; Bonds, M; Graham, NM; Madison, A; Sadaphal, P; Sheely, L; Sterling, TR; Thomas, DL; Vlahov, D, 2001) |
| "Annual skin testing for tuberculosis infection and anergy was performed, and eligible patients were offered daily isoniazid for 12 months and followed prospectively." | 7.70 | Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. ( Gourevitch, MN; Hartel, D; Klein, RS; Schoenbaum, EE; Selwyn, PA, 1999) |
| " This study compared completion rates for isoniazid (INH) preventive therapy for injection drug users (IDUs) randomly assigned to methadone treatment combined with directly observed preventive treatment (DOPT) versus those assigned to routine TB clinic referral without methadone treatment." | 6.70 | A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. ( Batki, SL; Bradley, JM; Bradley, M; Delucchi, K; Gruber, VA, 2002) |
| "Treatment with isoniazid was beneficial in HIV-infected, tuberculin-positive IDUs." | 5.32 | Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. ( Amofa, J; Driver, CR; Fujiwara, PI; Gourevitch, MN; Highley, E; Kaye, K; Munsiff, SS; Rubino, MA; Scholten, JN; Seewald, R; Trim, C, 2003) |
| "We conducted a randomized trial with a factorial design comparing strategies for improving adherence to isoniazid preventive therapy in 300 injection drug users with reactive tuberculin tests and no evidence of active tuberculosis." | 5.09 | A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. ( Barnes, GL; Cavalcante, S; Chaisson, RE; Hackman, J; Kimbrough , L; Metha, S; Moore, RD; Watkinson, L, 2001) |
| "The aims of this study were to (1) identify trends and risk factors for mycobacterial disease and (2) determine the effect of expanded access to isoniazid chemoprophylaxis on tuberculosis incidence." | 5.08 | Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. ( Astemborski, J; Bonds, M; Galai, N; Graham, NM; Nelson, KE; Rizzo, RT; Sheeley, L; Vlahov, D, 1996) |
| " Key recent developments to address HIV-related TB among PWIDs include the use of simplified symptom-based algorithm to provide isoniazid-preventive therapy, molecular DNA detection methods for Mycobacterium tuberculosis and the immediate provision of antiretroviral therapy within the first 2 weeks of initiation of anti-TB treatment." | 4.88 | Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services. ( Getahun, H; Gunneberg, C; Raviglione, M; Sculier, D; Verster, A, 2012) |
| "The prevalence of tuberculosis among HIV positive patients in Xinjiang was higher than in China taken as a whole, and HIV was diagnosed late, with underuse of isoniazid preventive therapy." | 3.85 | High prevalence and low cure rate of tuberculosis among patients with HIV in Xinjiang, China. ( Andersson, R; Maimaiti, R; Mijiti, P; Musa, M; Pan, K; Wubili, M; Zhang, Y, 2017) |
| "Isoniazid (INH) chemoprophylaxis has a positive impact on the development of clinical tuberculosis." | 3.71 | Reduction of clinical tuberculosis in HIV-infected males with isoniazid prophylaxis. ( Alaei, A; Alaei, K; Mansouri, D, 2002) |
| "Treatment of latent Mycobacterium tuberculosis infection with isoniazid can cause hepatotoxicity, but the risk of isoniazid-associated hepatotoxicity among persons coinfected with hepatitis C virus (HCV) is unknown." | 3.71 | Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. ( Astemborski, J; Bonds, M; Graham, NM; Madison, A; Sadaphal, P; Sheely, L; Sterling, TR; Thomas, DL; Vlahov, D, 2001) |
| "Annual skin testing for tuberculosis infection and anergy was performed, and eligible patients were offered daily isoniazid for 12 months and followed prospectively." | 3.70 | Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. ( Gourevitch, MN; Hartel, D; Klein, RS; Schoenbaum, EE; Selwyn, PA, 1999) |
| "Isoniazid prophylaxis in HIV-positive injecting drug users has been shown to significantly reduce the incidence of tuberculosis (TB)." | 3.69 | Isoniazid TB prophylaxis effective in drug users with HIV. ( , 1996) |
| " Overall, 33 percent of these patients had isolates resistant to one or more antituberculosis drugs, 26 percent had isolates resistant to at least isoniazid, and 19 percent had isolates resistant to both isoniazid and rifampin." | 3.68 | The emergence of drug-resistant tuberculosis in New York City. ( Cauthen, GM; Dooley, SW; Frieden, TR; Kilburn, JO; Pablos-Mendez, A; Sterling, T, 1993) |
| " This study compared completion rates for isoniazid (INH) preventive therapy for injection drug users (IDUs) randomly assigned to methadone treatment combined with directly observed preventive treatment (DOPT) versus those assigned to routine TB clinic referral without methadone treatment." | 2.70 | A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. ( Batki, SL; Bradley, JM; Bradley, M; Delucchi, K; Gruber, VA, 2002) |
| "Treatment with isoniazid was beneficial in HIV-infected, tuberculin-positive IDUs." | 1.32 | Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. ( Amofa, J; Driver, CR; Fujiwara, PI; Gourevitch, MN; Highley, E; Kaye, K; Munsiff, SS; Rubino, MA; Scholten, JN; Seewald, R; Trim, C, 2003) |
| " The median proportion of dosing days attended in 6 months was 96%." | 1.30 | Incentives and accessibility: a pilot study to promote adherence to TB prophylaxis in a high-risk community. ( Edlin, BR; Kral, AH; Lifson, AR; Lorvick, J; Thompson, S; Watters, JK, 1999) |
| "Forty-one of our patients had pulmonary tuberculosis, 38 had extra pulmonary and in 61 it was disseminated." | 1.28 | AIDS and tuberculosis in Spain. A report of 140 cases. ( Adrados, M; Díaz, F; García Aguado, C; González Lahoz, JM; Laguna, F; Martínez, R; Puente, S, 1991) |
| "The decision was analyzed for an intravenous drug abuser who may have been anergic, while tuberculin test status, race, and gender were varied." | 1.28 | Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis. ( Jordan, TJ; Lewit, EM; Montgomery, RL; Reichman, LB, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (62.50) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 2 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maimaiti, R | 1 |
| Zhang, Y | 1 |
| Pan, K | 1 |
| Mijiti, P | 1 |
| Wubili, M | 1 |
| Musa, M | 1 |
| Andersson, R | 1 |
| Getahun, H | 1 |
| Gunneberg, C | 1 |
| Sculier, D | 1 |
| Verster, A | 1 |
| Raviglione, M | 1 |
| Scholten, JN | 1 |
| Driver, CR | 1 |
| Munsiff, SS | 1 |
| Kaye, K | 1 |
| Rubino, MA | 1 |
| Gourevitch, MN | 3 |
| Trim, C | 1 |
| Amofa, J | 1 |
| Seewald, R | 1 |
| Highley, E | 1 |
| Fujiwara, PI | 1 |
| Alaei, K | 1 |
| Alaei, A | 1 |
| Mansouri, D | 1 |
| Fernández-Villar, A | 1 |
| Sopeña, B | 1 |
| García, J | 1 |
| Gimena, B | 1 |
| Ulloa, F | 1 |
| Botana, M | 1 |
| Martínez-Vázquez, C | 1 |
| Sánchez Fuentes, D | 1 |
| Barragán Casas, JM | 1 |
| Garcinuño Jiménez, MA | 1 |
| Martín Casado, M | 1 |
| Martín Marcos, M | 1 |
| Neville, K | 1 |
| Bromberg, A | 1 |
| Bromberg, R | 1 |
| Bonk, S | 1 |
| Hanna, BA | 1 |
| Rom, WN | 1 |
| Nolan, CM | 2 |
| Dunphy, CA | 1 |
| Krueger, LE | 1 |
| Goldbaum, GM | 1 |
| Wood, RW | 1 |
| Frieden, TR | 1 |
| Sterling, T | 1 |
| Pablos-Mendez, A | 1 |
| Kilburn, JO | 1 |
| Cauthen, GM | 1 |
| Dooley, SW | 1 |
| Rubinstien, EM | 1 |
| Madden, GM | 1 |
| Lyons, RW | 1 |
| Graham, NM | 2 |
| Galai, N | 1 |
| Nelson, KE | 1 |
| Astemborski, J | 2 |
| Bonds, M | 2 |
| Rizzo, RT | 1 |
| Sheeley, L | 1 |
| Vlahov, D | 2 |
| Jansà, JM | 1 |
| Serrano, J | 1 |
| Caylà, JA | 1 |
| Vidal, R | 1 |
| Ocaña, I | 1 |
| Español, T | 1 |
| Snyder, DC | 1 |
| Paz, EA | 1 |
| Mohle-Boetani, JC | 1 |
| Fallstad, R | 1 |
| Black, RL | 1 |
| Chin, DP | 1 |
| Pérez-Perdomo, R | 1 |
| Pérez-Cardona, CM | 1 |
| Hartel, D | 1 |
| Selwyn, PA | 1 |
| Schoenbaum, EE | 1 |
| Klein, RS | 1 |
| Lorvick, J | 1 |
| Thompson, S | 1 |
| Edlin, BR | 1 |
| Kral, AH | 1 |
| Lifson, AR | 1 |
| Watters, JK | 1 |
| Chaisson, RE | 1 |
| Barnes, GL | 1 |
| Hackman, J | 1 |
| Watkinson, L | 1 |
| Kimbrough , L | 1 |
| Metha, S | 1 |
| Cavalcante, S | 1 |
| Moore, RD | 1 |
| Perlman, DC | 1 |
| Trinh, C | 1 |
| Salomon, N | 1 |
| Horn, L | 1 |
| Des Jarlais, DC | 1 |
| Sadaphal, P | 1 |
| Sheely, L | 1 |
| Madison, A | 1 |
| Thomas, DL | 1 |
| Sterling, TR | 1 |
| Batki, SL | 1 |
| Gruber, VA | 1 |
| Bradley, JM | 1 |
| Bradley, M | 1 |
| Delucchi, K | 1 |
| Laguna, F | 1 |
| Adrados, M | 1 |
| Díaz, F | 1 |
| Martínez, R | 1 |
| García Aguado, C | 1 |
| Puente, S | 1 |
| González Lahoz, JM | 1 |
| Jordan, TJ | 1 |
| Lewit, EM | 1 |
| Montgomery, RL | 1 |
| Reichman, LB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PROvide MIner-friendly SErvices for Integrated TB/HIV Care in Lesotho Study (PROMISE Study)[NCT03537872] | 248 participants (Actual) | Interventional | 2018-03-13 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for isoniazid and Drug Abuse, Intravenous
| Article | Year |
|---|---|
Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services.
Topics: Antitubercular Agents; Chemoprevention; Comorbidity; Harm Reduction; Hepatitis B; Hepatitis C; HIV I | 2012 |
Community-wide implementation of targeted testing for and treatment of latent tuberculosis infection.
Topics: Emigration and Immigration; Humans; Ill-Housed Persons; Isoniazid; Managed Care Programs; Prisons; S | 1999 |
3 trials available for isoniazid and Drug Abuse, Intravenous
| Article | Year |
|---|---|
Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antitubercular Agents; Female; | 1996 |
A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users.
Topics: Adult; Antitubercular Agents; Counseling; Female; Humans; Isoniazid; Male; Middle Aged; Patient Comp | 2001 |
A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users.
Topics: Adult; Analysis of Variance; Antitubercular Agents; Chi-Square Distribution; Directly Observed Thera | 2002 |
19 other studies available for isoniazid and Drug Abuse, Intravenous
| Article | Year |
|---|---|
High prevalence and low cure rate of tuberculosis among patients with HIV in Xinjiang, China.
Topics: Adult; Chemoprevention; China; Coinfection; Cross-Sectional Studies; Female; HIV Infections; HIV-1; | 2017 |
Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; HIV; HIV Infectio | 2003 |
Reduction of clinical tuberculosis in HIV-infected males with isoniazid prophylaxis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Chemoprevention; Humans; Incide | 2002 |
Hepatitis C virus RNA in serum as a risk factor for isoniazid hepatotoxicity.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Female; Hepatitis C Antibodies | 2007 |
[Decision regarding chemoprophylaxis with isoniazid in patients using parenteral drugs and infected with HIV].
Topics: Decision Support Techniques; Decision Trees; HIV Infections; Humans; Isoniazid; Substance Abuse, Int | 1994 |
The third epidemic--multidrug-resistant tuberculosis.
Topics: Adult; Age Factors; Comorbidity; Disease Outbreaks; Drug Resistance, Microbial; Ethambutol; Female; | 1994 |
Low prevalence of positive tuberculin tests in homo-/bisexual white men from Seattle: implications for anergy testing.
Topics: Adult; Bisexuality; Comorbidity; False Negative Reactions; HIV Infections; Homosexuality; Humans; Im | 1993 |
The emergence of drug-resistant tuberculosis in New York City.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antitubercular Agents; Centers for Disease Co | 1993 |
Active tuberculosis in HIV-infected injecting drug users from a low-rate tuberculosis area.
Topics: Antitubercular Agents; Connecticut; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; Is | 1996 |
Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Cohort Studies; Female; HIV Inf | 1998 |
Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Cost-Benefit Analysis; Drug The | 1999 |
An epidemiological review of tuberculosis in the Puerto Rican population.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Canada; Child; | 1999 |
Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antitubercular Age | 1999 |
Incentives and accessibility: a pilot study to promote adherence to TB prophylaxis in a high-risk community.
Topics: Adult; Antitubercular Agents; Community Health Services; Drug Administration Schedule; Female; Healt | 1999 |
Isoniazid TB prophylaxis effective in drug users with HIV.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Sub | 1996 |
Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Cost-Benefit Analys | 2001 |
Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis.
Topics: Adult; Antibiotic Prophylaxis; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Female | 2001 |
AIDS and tuberculosis in Spain. A report of 140 cases.
Topics: Acquired Immunodeficiency Syndrome; Drug Therapy, Combination; Ethambutol; Female; Humans; Incidence | 1991 |
Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Decision Trees; HIV Infections; HIV Seropositivity; H | 1991 |